Fujifilm Europe has introduced the new EW10-VM01 software for SCALE EYE real-time virtual scale function, which is designed to help endoscopists estimate the size of lesions in the colon.
Designed for the real-time detection and characterisation of lesions, SCALE EYE is the company’s latest technology to be introduced as part of the ELUXEO Ultra platform.
The EW10-VM01 software can be deployed in the expansion unit EX-1 and used with CAD EYE, a colon polyp detection and characterisation function.
SCALE EYE has been designed to help endoscopists estimate the size of lesions in the colon by simply pressing the endoscope switch.
The recently developed endoscope EC-760S-A/M, L is included in the software. EC-760S-A/M, L is equipped with a class one laser, the point of which is visible in the endoscopic image.
The laser point position changes according to the distance between the tip of the endoscope and the object.
The scale interval size automatically adjusts depending on the laser point position.
Fujifilm Europe senior product manager Saskia Papa said: “SCALE EYE is yet another technological leap forward in the fight against colorectal cancer by targeting challenges faced by colonoscopists.
“It is widely known that whilst detection and accurate characterisation of lesions has an impact on the occurrence of interval cancers, accurate measurement of lesions is vital in not only assigning appropriate surveillance intervals but also to determine the most appropriate course of therapy.
“With SCALE EYE, we have a real chance to further support physicians in improving the quality of colonoscopy, from screening through to treatment, and to ultimately improve the lives of patients.”
The company stated that the SCALE EYE system provides scale sizes of 5mm, 10mm and 20mm.
The endoscope switch operates the activation and deactivation of the system.
In 2020, Colorectal cancer was the second most frequently occurring cancer in Europe and accounted for 12.7% of all new cancer diagnoses.
Fujifilm noted that the early detection and diagnosis of the disease, as well as pre-cancerous lesions, would significantly reduce treatment complexity and improve patient outcomes.
Lesion size is considered to be one of the most important factors in making treatment decisions.